Oral Communications : These results are from the ANRS 174 Doxyvac clinical trial, a study of combination prevention of sexually transmitted infections (STIs) in men who have sex with men using oral TDF/FTC for HIV pre-exposure prophylaxis (PrEP)
Oral Session Feb. 20, 2023 - HIV AND STI PREVENTION: NEW TOOLS ANDAPPROACHES: ANRS 174 DOXYVAC An Open-Label Randomized trial to Prevent STIs in MSM on PrEP. Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Algarté-Génin Michele, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Cecile Bebear, Nicolas Dupin, Jean-Paul Viard, Juliette Pavie, Claudine Duvivier, Jade Ghosn, Dominique Costagliola. Research Group: ANRS 174 Doxyvac Group
Oral Session - Oral Session Feb. 22,2023 - EPIDEMIOLOGY AND PREVENTION OF MPOX AND SARS-CoV-2 : Impact of vaccination on mpox incidence in MSM on PrEP in the ANRS 174 DOXYVAC trial. Jade Ghosn, Lambert Assoumou, Moussa Ouattara, Michele Algarté-Génin, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Claudine Duvivier, Juliette Pavie, Jean-Paul Viard, Severine Gibowski, Manon Ollivier, Dominique Costagliola, Jean-Michel Molina
Posters :
Poster Session-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESIVIR. Poster 560- Remdesivir in hospitalized covid-19 patients : individual patient data meta-analysis. Alain Amstutz, Benjamin Speich, France Mentré., Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel
Poster Session-R1 : MOLECULAR HIV EPIDEMIOLOGY. Poster 844- Epidemiological and molecular evolution of the HIV-1 CRF94 : birth of CRF132. Marc Wirden, Fabienne De-Oliveira, Marie-Laure Chaix, Stéphanie Marque-Juillet , Sidonie Lambert-Niclot , Basma Abdi , Charlotte Charpentier , Benedicte Roquebert ; Jean-Christophe Plantier, Diane Descamps , Vincent Calvez , Anne-Genevieve Marcelin , Benoit Visseaux , for the The Agence Nationale de Recherche sur le SIDA, les hépatites et maladies émergentes (ANRS-MIE group). This collaborative work, carried out with the ANRS and Maladies Emergentes network, describes the epidemiological and molecular evolution of the transmission cluster involving the HIV-1 recombinant CRF94_02BF2 discovered in 2017. In June 2022, this CRF94 cluster included 63 MSM but only 2 infections were detected after 2019. At the same time, a new strain was discovered resulting from the recombination of CRF94 with a B subtype giving rise to CRF132_94B. This new recombinant was involved in a new cluster of 32 MSM including 29 diagnosed after 2019. The virological and immunological data suggest a lower virulence of CRF132 compared to CRF94, probably due to the change of subtype of the vif gene from F2 to B.